Helus Pharma (DE:R7E)
FRANKFURT:R7E
R7E Stock Chart & Stats
€4.46
-€0.55(-5.53%)
At close: 4:00 PM EST
€4.46
-€0.55(-5.53%)
Day’s Range― - ―
52-Week Range€3.08 - €8.10
Previous CloseN/A
Volume0.00
Average Volume (3M)470.00
Market Cap
€1.18M
Enterprise Value€0.00
Total Cash (Recent Filing)€116.53M
Total Debt (Recent Filing)€40.19M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Jul 01, 2026EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.01
Shares Outstanding50,035,793
10 Day Avg. Volume1,211
30 Day Avg. Volume470
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)7.14
Price to Sales (P/S)0.00
P/FCF Ratio-16.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€44.49Price Target Upside897.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And DurabilityAnalyst highlights pooled patient results that showed sustained anxiety improvement and a durable response after treatment, suggesting the therapy could provide longer-lasting symptom relief than many existing psychiatric options.
Drug Design And PatentabilityAnalyst points out that the company's deuteration approach is intended to slow metabolism and enhance patentability, which may enable more predictable dosing and commercial differentiation versus first-generation psychedelic treatments.
Regulatory RecognitionAnalyst notes that the lead oral deuterated candidate received an FDA breakthrough designation, indicating regulatory acknowledgment that could streamline development and reduce approval uncertainty.
Bears Say
Confounding Factors In Clinical DataAnalyst cautions that allowing patients to continue existing medications during the trial likely blurred the ability to isolate the investigational drug's effect, weakening confidence in the efficacy signal.
Market Access And Financial Dilution RiskAnalyst warns that reimbursement dynamics favoring later-line use and assumptions of future equity raises could limit commercial uptake and dilute shareholder value, heightening execution and financial risk.
Trial Design And Inconclusive ResultsAnalyst describes the HLP004 Phase 2 findings as inconclusive because low and high doses produced similar improvements and the small sample size reduced clarity on true efficacy differences.
Helus Pharma News
R7E FAQ
What was Helus Pharma’s price range in the past 12 months?
Helus Pharma lowest stock price was €3.08 and its highest was €8.10 in the past 12 months.
What is Helus Pharma’s market cap?
Helus Pharma’s market cap is €1.18M.
When is Helus Pharma’s upcoming earnings report date?
Helus Pharma’s upcoming earnings report date is Jul 01, 2026 which is in 15 days.
How were Helus Pharma’s earnings last quarter?
Helus Pharma released its earnings results on Feb 13, 2026. The company reported -€0.84 earnings per share for the quarter, missing the consensus estimate of -€0.644 by -€0.197.
Is Helus Pharma overvalued?
According to Wall Street analysts Helus Pharma’s price is currently Undervalued.
Does Helus Pharma pay dividends?
Helus Pharma does not currently pay dividends.
What is Helus Pharma’s EPS estimate?
Helus Pharma’s EPS estimate is -0.69.
How many shares outstanding does Helus Pharma have?
Helus Pharma has 50,035,793 shares outstanding.
What happened to Helus Pharma’s price movement after its last earnings report?
Helus Pharma reported an EPS of -€0.84 in its last earnings report, missing expectations of -€0.644. Following the earnings report the stock price went up 0.98%.
Which hedge fund is a major shareholder of Helus Pharma?
Currently, no hedge funds are holding shares in DE:R7E
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Helus Pharma
Cybin Inc. is a biopharmaceutical firm dedicated to advancing treatments derived from psychedelic compounds. Its active research and development portfolio features several key candidates: CYB003, a modified psilocybin compound targeting major depressive and alcohol use disorders; CYB004, a deuterated form of dimethyltryptamine aimed at anxiety conditions; and CYB005, a phenethylamine derivative designed to address neuroinflammation. Additionally, Cybin has introduced EMBARK, a therapeutic approach incorporating psychedelic-assisted psychotherapy. The company's main operations are situated in Toronto, Canada.
R7E Stock 12 Month Forecast
Average Price Target
€44.49
▲(897.56% Upside)
Technical Analysis
Options Prices
Currently, No data available
---